{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:36:03Z","timestamp":1792082163773,"version":"4.4.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Clinical Electrophysiology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.jacep.2018.06.004","type":"journal-article","created":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T18:17:56Z","timestamp":1535566676000},"page":"1491-1500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":178,"title":["Ibrutinib-Associated Atrial Fibrillation"],"prefix":"10.1016","volume":"4","author":[{"given":"Sarju","family":"Ganatra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam M.","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas G.","family":"Neilan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Saad","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Barac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Groarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim S.","family":"Hayek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurbha","family":"Dani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Venesy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Patten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju","family":"Nohria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacep.2018.06.004_bib1","unstructured":"Centers for Disease Control and Prevention. Leading Causes of Death and Numbers of Deaths, by Sex, Race, and Hispanic Origin: United States, 1980 and 2014 (Table\u00a019). Available at: https:\/\/www.cdc.gov\/nchs\/hus\/contents2015.htm. Accessed\u00a0April 30,\u00a02018."},{"key":"10.1016\/j.jacep.2018.06.004_bib2","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jacc.2013.11.026","article-title":"Insights into onco-cardiology: atrial fibrillation in cancer","volume":"63","author":"Farmakis","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacep.2018.06.004_bib3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ijcard.2012.08.036","article-title":"Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients","volume":"165","author":"Hu","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacep.2018.06.004_bib4","series-title":"Pharmacyclics. Ibrutinib (Ibruvica) [package insert]","year":"2015"},{"key":"10.1016\/j.jacep.2018.06.004_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clml.2016.09.010","article-title":"Risk of atrial fibrillation and bleeding diathesis associated with ibrutinib treatment: a systematic review and pooled analysis of four randomized controlled trials","volume":"17","author":"Yun","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jacep.2018.06.004_bib6","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/bloodadvances.2017009720","article-title":"Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib","volume":"1","author":"Wiczer","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jacep.2018.06.004_bib7","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","article-title":"Ventricular arrhythmias and sudden death in patients taking ibrutinib","volume":"129","author":"Lampson","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jacep.2018.06.004_bib8","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacep.2018.06.004_bib9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacep.2018.06.004_bib10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacep.2018.06.004_bib11","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacep.2018.06.004_bib12","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstrom's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacep.2018.06.004_bib13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jacep.2018.06.004_bib14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacep.2018.06.004_bib15","doi-asserted-by":"crossref","first-page":"957","DOI":"10.2217\/fon.14.51","article-title":"Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase","volume":"10","author":"Davids","year":"2014","journal-title":"Future Oncol"},{"key":"10.1016\/j.jacep.2018.06.004_bib16","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1182\/blood-2014-01-549493","article-title":"Lymphocytosis and ibrutinib treatment of CLL","volume":"123","author":"Rossi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jacep.2018.06.004_bib17","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacep.2018.06.004_bib18","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/europace\/eup300","article-title":"Introducing a new entity: chemotherapy-induced arrhythmia","volume":"11","author":"Guglin","year":"2009","journal-title":"Europace"},{"key":"10.1016\/j.jacep.2018.06.004_bib19","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1182\/blood.V126.23.2933.2933","article-title":"Atrial fibrillation in CLL\/SLL patients on ibrutinib","volume":"126","author":"Farooqui","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jacep.2018.06.004_bib20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","article-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial","volume":"15","author":"O'Brien","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jacep.2018.06.004_bib21","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(14)70335-3","article-title":"Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study","volume":"15","author":"Burger","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jacep.2018.06.004_bib22","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study","volume":"17","author":"Chanan-Khan","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jacep.2018.06.004_bib23","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacep.2018.06.004_bib24","first-page":"92","article-title":"Results from the phase 2 RESONATE\u2122-17 trial: efficacy and safety of Ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma with Del17p","volume":"38 Suppl 5","author":"Stilgenbauer","year":"2015","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.jacep.2018.06.004_bib25","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1182\/blood-2014-12-617522","article-title":"Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b\/2 study","volume":"126","author":"Jaglowski","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jacep.2018.06.004_bib26","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jacep.2018.06.004_bib27","doi-asserted-by":"crossref","first-page":"E312","DOI":"10.1002\/ajh.24366","article-title":"Atrial fibrillation associated with ibrutinib in Waldenstrom macroglobulinemia","volume":"91","author":"Gustine","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jacep.2018.06.004_bib28","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1182\/blood.V126.23.4529.4529","article-title":"Bruton's tyrosine kinase inhibition is associated with manageable cardiac toxicity","volume":"126","author":"Romisher","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jacep.2018.06.004_bib29","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/eurheartj\/ehi825","article-title":"Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study","volume":"27","author":"Heeringa","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacep.2018.06.004_bib30","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1161\/01.CIR.96.7.2455","article-title":"Incidence of and risk factors for atrial fibrillation in older adults","volume":"96","author":"Psaty","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.jacep.2018.06.004_bib31","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jacep.2018.06.004_bib32","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1073\/pnas.0606663104","article-title":"Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy","volume":"104","author":"McMullen","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacep.2018.06.004_bib33","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2353\/ajpath.2009.090126","article-title":"Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation","volume":"175","author":"Pretorius","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jacep.2018.06.004_bib34","doi-asserted-by":"crossref","first-page":"e000596","DOI":"10.1136\/openhrt-2017-000596","article-title":"Necessity to evaluate PI3K\/Akt signalling pathway in proarrhythmia","volume":"4","author":"Ezeani","year":"2017","journal-title":"Open Heart"},{"key":"10.1016\/j.jacep.2018.06.004_bib35","doi-asserted-by":"crossref","first-page":"A14587","DOI":"10.1161\/circ.132.suppl_3.14587","article-title":"Abstract 14587: proarrhythmic effects of ibrutinib, a clinically approved inhibitor of Bruton\u2019s tyrosine kinase (BTK) used in cancer therapy","volume":"132","author":"Yang","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacep.2018.06.004_bib36","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1016\/j.jacc.2014.03.021","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society","volume":"64","author":"January","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacep.2018.06.004_bib37","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1200\/JCO.2000.18.17.3078","article-title":"Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis","volume":"18","author":"Hutten","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacep.2018.06.004_bib38","series-title":"National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v4.03","year":"2010"},{"key":"10.1016\/j.jacep.2018.06.004_bib39","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1016\/S0735-1097(17)35697-8","article-title":"Challenges in ibrutinib associated atrial fibrillation","volume":"11","author":"Ganatra","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacep.2018.06.004_bib40","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1161\/ATVBAHA.115.306130","article-title":"Ibrutinib inhibits platelet integrin alphaIIbbeta3 outside-in signaling and thrombus stability but not adhesion to collagen","volume":"35","author":"Bye","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacep.2018.06.004_bib41","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.3324\/haematol.2016.155978","article-title":"Effects of ibrutinib treatment on murine platelet function during inflammation and in primary hemostasis","volume":"102","author":"Lee","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.jacep.2018.06.004_bib42","doi-asserted-by":"crossref","first-page":"178","DOI":"10.18773\/austprescr.2015.065","article-title":"Ibrutinib","volume":"38","year":"2015","journal-title":"Aust Prescr"},{"key":"10.1016\/j.jacep.2018.06.004_bib43","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/CIRCULATIONAHA.116.023163","article-title":"Modifiable risk factors and atrial fibrillation","volume":"136","author":"Lau","year":"2017","journal-title":"Circulation"}],"container-title":["JACC: Clinical Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405500X18304766?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405500X18304766?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T07:26:46Z","timestamp":1762500406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405500X18304766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S2405500X18304766"],"URL":"https:\/\/doi.org\/10.1016\/j.jacep.2018.06.004","relation":{},"ISSN":["2405-500X"],"issn-type":[{"value":"2405-500X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ibrutinib-Associated Atrial Fibrillation","name":"articletitle","label":"Article Title"},{"value":"JACC: Clinical Electrophysiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacep.2018.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}